Pharmaceuticals News and Research

RSS

CPEX Pharmaceuticals completes enrollment in Nasulin Phase 2a clinical trial

CPEX Pharmaceuticals, Inc. today announced that the ongoing Phase 2a clinical trial of Nasulin™, the Company’s intranasal insulin candidate, has now completed enrollment. The study was initiated in February of this year and randomized 94 subjects. Results are expected at the end of the first quarter or beginning of the second quarter of 2010.

21 Dec 2009

Investigation of IDH1 gene mutations in brain cancer receives new funds

Agios Pharmaceuticals, the leading biopharmaceutical company focused on discovering and developing novel drugs in the emerging field of cancer metabolism, announced today that it has received funding from Accelerate Brain Cancer Cure (ABC2), a non-profit organization that supports brain cancer research. ABC2’s funding will enable new research investigating IDH1 gene mutations in brain cancer, with the goal of supplementing Agios’s ongoing research into the development of new IDH1 therapeutics and diagnostics.

21 Dec 2009

Durata Therapeutics acquires Vicuron Pharmaceuticals

Durata Therapeutics, Inc. announced today that it has acquired Vicuron Pharmaceuticals from Pfizer (PFE). Durata is a newly formed biopharmaceutical company that was created by a five-member venture capital syndicate to pursue late-stage clinical development of novel antibiotic programs. The acquisition was funded through a stock purchase by New Leaf Venture Partners, LLC, Domain Associates, LLC, Aisling Capital, Sofinnova Ventures Inc. and Canaan Partners.

21 Dec 2009

Swedish agency approves Medivir's Xerclear for treatment of cold sores

The Swedish Medical Products Agency has now approved Xerclear™ for treatment of cold sores. It is the first and only topical treatment that has been demonstrated to prevent the incidence of cold sores and shorten healing-times. Xerclear™ will be available from pharmacies in the first half-year 2010.

21 Dec 2009

Preliminary results from Phase III study of afamelanotide in EPP announced

Clinuvel Pharmaceuticals Limited today announced that it has obtained promising 4-months results in testing afamelanotide in a multicentre randomised double-blind placebo controlled Phase III study in EPP (CUV017).

21 Dec 2009

FreedomWorks opposes proposed health care legislation

While a blizzard paralyzed Washington, it did not slow down the health care legislative stampede on Capitol Hill. The bill being rushed through by Senator Harry Reid and Senate Democrat leadership will fundamentally alter American health care.

21 Dec 2009

Data released by CIHI supports CNA's vision on nursing and health

A growing number of registered nurses (RNs) and nurse practitioners (NPs) are working in positions of first point of contact between patients and the health-care system, helping improve patient access to primary care and driving down wait times.

19 Dec 2009

'Help is Here Express' helps uninsured and financially-struggling patients with free prescription medicines

The Beaches Leader recently reported that the "Help is Here Express" bus tour visited Jacksonville Beach's Mission House to help uninsured and financially-struggling patients access information on programs that provide prescription medicines for free or nearly free.

19 Dec 2009

RPC's China-based subsidiary signs strategic advisory agreement with SRA

US-based pharmaceutical company Radient Pharmaceuticals Corporation (RPC) (NYSE Amex: RPC) announced today its China-based subsidiary Jade Pharmaceutical, Inc. ("JPI"), of which RPC owns approximately 98%, has signed a strategic advisory agreement with Security Research Associates, Inc. ("SRA").

19 Dec 2009

Raptor Pharmaceutical enters into definitive agreements with institutional investors to purchase 3.7M units

Raptor Pharmaceutical Corp., today announced that it has entered into definitive agreements with institutional investors to purchase 3,747,558 units for gross proceeds of approximately $7.5 million, before placement agent fees and offering expenses.

19 Dec 2009

Fitch Ratings announces Covidien rating outlook stable

Fitch Ratings has affirmed Covidien plc's (Covidien) ratings.

19 Dec 2009

Canadian clinical trials move over to electronic data capture tools

A research team led by Dr. Khaled El Emam, the Canada Research Chair in Electronic Health Information at the CHEO Research Institute, evaluated the use of technology in Canadian clinical trials, and found that a significant proportion (41%) have moved away from collecting and managing trial data using only paper records.

19 Dec 2009

Akorn exits vaccine distribution business

Akorn, Inc. today announced that it failed to reach an amicable resolution to a longer term and strategic business arrangement with the supplier of its Tetanus Diphtheria (“Td”) vaccine and as a result will be exiting the business. The existing supply agreement will end on March 14, 2010. The company previously announced its intent to exit the distribution of flu vaccines.

19 Dec 2009

158 of American Oriental Bioengineering's drugs included in China's 2009 NIC

American Oriental Bioengineering, Inc., ("the Company" or "AOBO"), a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter ("OTC") products, today announced that 158 of the Company's drugs have been included in China's National (Medical) Insurance Catalog (the "2009 NIC").

19 Dec 2009

KVCI completes acquisition of former AAIPharma bioanalytical division

Kansas Venture Capital, Inc. (KVCI) has acquired the former AAIPharma bioanalytical division from ZeeCRO Inc. With its 30-year track record of developing entrepreneurial companies, KVCI will grow the bioanalytical business through organic and acquisition strategies to provide best-in-class analytical services for both the pharmaceutical and life sciences sectors.

18 Dec 2009

Taro Pharmaceutical Industries initiates its T2007 non-sedating barbiturate compound Phase I clinical trials

Taro Pharmaceutical Industries Ltd. announced that it has begun Phase I clinical trials in Canada with T2007, the second in the Company’s class of proprietary non-sedating barbiturate compounds to be approved for studies in humans.

18 Dec 2009

H1N1 cases still increasing in many countries; WHO to begin shipping donated vaccines within weeks

With many countries continuing to report a growing number of H1N1 (swine flu) cases, Keiji Fukuda, special adviser to the WHO director general on pandemic influenza, said Thursday it was too early to declare the pandemic over, the Washington Post reports.

18 Dec 2009

GSK receives European CHMP positive opinion for Revolade

Ligand Pharmaceuticals Incorporated today announced that its partner GlaxoSmithKline has received a positive opinion for Revolade® (eltrombopag/Promacta®) from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for the oral treatment of thrombocytopenia (reduced platelet count) in adults with the blood disorder chronic immune (idiopathic) thrombocytopenic purpura (ITP).

18 Dec 2009

Leerink Swann announces availability of its 2010 healthcare investment outlook report

Leerink Swann, the leading healthcare-focused investment banking firm, today announced the availability of the firm’s 2010 healthcare investment outlook report.

18 Dec 2009

Danaher offers GBP 50 million pounds for Genetix Group acquisition

Danaher Corporation announced today its intention to make a recommended cash takeover offer, through an indirect wholly owned subsidiary, to acquire all of the issued and to be issued shares of Genetix Group plc for 85 pence per share implying an aggregate price of approximately GBP 50 million pounds (USD $82 million) net of cash acquired.

From Danaher 18 Dec 2009